Hong Kong Regen Medtech

Hong Kong Regen Medtech Limited (HKRM) is a biotechnology company based in the Hong Kong Science Park that specializes in the development of advanced stem cell therapies and regenerative medicine. Founded in 2019, the company focuses on treating intractable, degenerative, and immunological diseases using a proprietary platform that mimics native developmental niches for stem cell manipulation. HKRM's pipeline includes umbilical cord-derived mesenchymal stem cell (MSC) injections for acute-on-chronic liver failure and MSC-derived secretome therapies for osteoarthritis, supported by strategic partnerships with AmcellGene and Cordlife. The company is also establishing a PIC/S GMP-certified advanced therapy product (ATP) cell processing facility to facilitate the commercialization of its cellular products in Asia. Additionally, HKRM is active in the longevity sector, providing scientific insights and products related to NMN supplementation.